<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01978587</url>
  </required_header>
  <id_info>
    <org_study_id>AZ951-U-13-005</org_study_id>
    <nct_id>NCT01978587</nct_id>
  </id_info>
  <brief_title>Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease</brief_title>
  <official_title>A Phase 1, Open-label, Sequential Crossover Study to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akros Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akros Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics
      (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage
      renal disease (ESRD) receiving hemodialysis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (maximum concentration) of JTZ-951 when administered before and after hemodialysis</measure>
    <time_frame>Days 1 to 4 and 8 to 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time to reach maximum concentration) of JTZ-951 when administered before and after hemodialysis</measure>
    <time_frame>Days 1 to 4 and 8 to 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC (area under the concentration-time curve) of JTZ-951 when administered before and after hemodialysis</measure>
    <time_frame>Days 1 to 4 and 8 to 11</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (elimination half-life) of JTZ-951 when administered before and after hemodialysis</measure>
    <time_frame>Days 1 to 4 and 8 to 11</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and ECG (electrocardiogram)</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Anemia in Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Dose 1 JTZ-951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, 1 dose on Day 1 before hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 JTZ-951</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablets, 1 dose on Day 8 after hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JTZ-951</intervention_name>
    <arm_group_label>Dose 1 JTZ-951</arm_group_label>
    <arm_group_label>Dose 2 JTZ-951</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have ESRD and have been receiving maintenance hemodialysis for at least
             12 weeks prior to the Screening Visit

          -  Body weight (post-dialysis weight) greater than 45.0 kg and a body mass index between
             20.0 and 40.0 kg/m2 (inclusive) at the Screening Visit

        Exclusion Criteria:

          -  Acute coronary syndrome (e.g., myocardial infarction) within 1 year prior to admission

          -  Uncontrolled hypertension at the Screening Visit or Day -1
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hideyuki Yamamoto</last_name>
    <role>Study Chair</role>
    <affiliation>Akros Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2013</study_first_submitted>
  <study_first_submitted_qc>November 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 7, 2013</study_first_posted>
  <last_update_submitted>March 15, 2014</last_update_submitted>
  <last_update_submitted_qc>March 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>End-stage Renal Disease</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Pharmacokinetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

